But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Investor's Business Daily on MSN1d
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Taco Bell reintroduces value menu, Supreme Court considers TikTok ban, and coffee drinks lower risk of heart disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback